Tofacitinib etocomil

伊托法替布

Report date: 2026/04/23 16:21:15
NME

Base Information

Drug NameTofacitinib etocomil
Drug Alias NameMH-004
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionJanus kinase inhibitors
TargetsJanus kinase
Therapy Area/IndicationsAutoimmune DiseasesVitiligoDermatitis, Atopic +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusNDA/BLA
Highest Status in ChinaNDA/BLA
Originator CompaniesMinghui Pharmaceutical (Shanghai) Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesMinghui Pharmaceutical (Hangzhou) Co LtdMing Ren Pharmaceutical Ltd
Inactive CompaniesMinghui Pharmaceutical Pty Ltd
Active IndicationsAutoimmune DiseasesVitiligoDermatitis, Atopic
Inactive IndicationsArthritis, Rheumatoid

Other Information

ATC CodeN/A
Related LinksN/A